Purple Biotech (PPBT) Net Income towards Common Stockholders (2014 - 2026)
Purple Biotech (PPBT) reported Net Income towards Common Stockholders of $86000.0 for Q1 2026, down 81.02% year-over-year from $453000.0 in Q1 2025, and down 99.63% quarter-over-quarter from $23.5 million in Q4 2025.
Purple Biotech (PPBT) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 13 years of Net Income towards Common Stockholders data on file, last reported at $86000.0 in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $86000.0, down 81.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.0 million (up 560.91% YoY), and the FY2025 annual result was -$26.4 million, down 264.45% from the prior year.
- Net Income towards Common Stockholders fell to $86000.0 in Q1 2026 per PPBT's latest filing, from $23.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $23.5 million in Q4 2025 and troughed at $86000.0 in Q1 2026.
- A 5-year average of $4.4 million and a median of $3.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 91.51% in 2024, then jumped 5642.93% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $6.0 million in 2022, then fell by 19.68% to $4.8 million in 2023, then tumbled by 91.51% to $410000.0 in 2024, then jumped by 5642.93% to $23.5 million in 2025, then plunged by 99.63% to $86000.0 in 2026.
- Business Quant data shows PPBT's Net Income towards Common Stockholders at $86000.0 in Q1 2026, $23.5 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 23.55 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 453,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 663,000.00 |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 3.78 Mn |
| Dec 31, 2023 | 4.83 Mn |
| Sep 30, 2023 | 5.04 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 7.30 Mn |
| Dec 31, 2021 | 5.07 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Jun 30, 2021 | 3.64 Mn |